Samuel Newell, MD
Neurology · Tupelo, MSNPI 1962495192
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,003 of the $9,888 with a category attached, or 80.9%. 38 manufacturers reported payments, led by AbbVie at 30.6% of the total. Reporting peaked in 2023 at $3,215 and has fallen 73.1% since, to $863 in 2025.
Across 498 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Livanova USA, Inc.$2K
- Acorda Therapeutics, Inc$469
- Pfizer$461
- Teva Pharmaceuticals USA, Inc.$418
- Sanofi$340
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$4294%
- Travel & lodging$1,45615%
- Food & beverage$8,00381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 203 | $3,022 |
| Livanova USA, Inc. | 17 | $2,183 |
| Acorda Therapeutics, Inc | 24 | $469 |
| Pfizer | 34 | $461 |
| Teva Pharmaceuticals USA, Inc. | 27 | $418 |
| Sanofi | 19 | $340 |
| SK Life Science, Inc. | 13 | $298 |
| Harmony Biosciences LLC | 10 | $283 |
| Medtronic(2 entities) | 16 | $240 |
| Piramal Critical Care | 8 | $221 |
| Biohaven Pharmaceuticals, Inc. | 16 | $208 |
| Bristol Myers Squibb | 12 | $183 |
| Amgen | 10 | $177 |
| Biogen | 7 | $125 |
| Supernus Pharmaceuticals, Inc. | 10 | $124 |
| AstraZeneca | 4 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $119 |
| Amneal Pharmaceuticals LLC | 7 | $104 |
| Genentech USA, Inc. | 7 | $99 |
| Lilly USA, LLC | 6 | $90 |
| Lundbeck LLC | 5 | $88 |
| Avanir Pharmaceuticals, Inc. | 5 | $64 |
| Neurocrine Biosciences, Inc. | 4 | $61 |
| UCB, Inc. | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Catalyst Pharmaceuticals, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| CSL Behring | 2 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| GE HealthCare | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Resmed Corp | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,851
- GABLOFEN$468
- MITIGO$117
How this compares
$9,888 in reported general payments places this provider in the 70th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $318,687 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $177,088 |
| Tetrabenazine | 23 | $66,516 |
| TecfideraDimethyl Fumarate | 14 | $60,698 |
| NuplazidPimavanserin Tartrate | 12 | $58,028 |
| Emgality PenGalcanezumab-Gnlm | 65 | $44,376 |
| UbrelvyUbrogepant | 21 | $29,839 |
| Nurtec OdtRimegepant Sulfate | 21 | $22,460 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $22,133 |
| Levetiracetam | 163 | $5,571 |
| AdlarityDonepezil Hcl | 12 | $5,310 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 126 | $2,981 |
| Gabapentin | 141 | $2,723 |
| Lacosamide | 34 | $2,229 |
| Zolmitriptan OdtZolmitriptan | 19 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $26 | $318,68718 claims |
| BiogenTecfidera | $125 | $60,69814 claims |
| Acadia Pharmaceuticals IncNuplazid | $22 | $58,02812 claims |
| AbbVieUbrelvy | $3,022 | $29,83921 claims |
| PfizerNurtec Odt | $461 | $22,46021 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $104 | $2,41046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 neurology providers in Mississippi.
Other neurology in Tupelo
- Stephen LandyTupelo$1.9M
- Justin GraffTupelo$85K
- Mark FletcherTupelo$41K
- Donna HarringtonTupelo$6K
- William OakesTupelo$3K
- Ali AhmadTupelo$2K
- Esther FischerTupelo$2K
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Ronald SchwartzHattiesburg$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.